Research

Rigel, Evotec OAI Collaborate To Identify Ubiquitin Ligase Inhibitors

Published in Cancer Weekly, November 13th, 2001

Rigel Pharmaceuticals Inc., a drug discovery and development company, and Evotec OAI AG, Hamburg, Germany (EVT), a supplier of integrated drug discovery services, have signed a medicinal chemistry agreement for the optimization of small molecules focused on inhibitors of ubiquitin ligases.

Ubiquitin ligases are involved in cell division and the progression of certain cancers. Research on this target class is an important new area in the field of oncology. Rigel focuses on the study ubiquitin ligases and their applications in oncologic, inflammatory and viral diseases.

Under the terms of the agreement, Evotec OAI will use its integrated drug...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2001-11-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry